A meta-analysis of mood stabilizers for Alzheimer’s disease

Abstract

The objective of this study was to assess the clinical evidence for or against mood stabilizers as a treatment for Alzheimer’s disease (AD). We searched 5 databases from their inception to January 2010. Five randomized clinical trials of mood stabilizers to treat human patients suffering from AD were included. These trials assessed the effectiveness of mood stabilizers as an adjunct treatment to conventional anti-dementia drugs on behavioral and psychological symptoms, especially on agitation. Methodological quality was assessed using the Jadad score. The results suggested a significant effect in favor of placebo on the Mini-Mental Status Examination [n=270, weight mean difference (WMD), −0.89; 95% confidence intervals (CIs) −1.69 to −0.09, P=0.03] and on the Neuropsychiatric Inventory total (NPI total) (n=51, WMD, 3.71; 95% CIs 0.15 to 7.26, P=0.04). There were no significant differences in change scores on total Brief Psychiatric Rating Scale (BPRS total), NPI/BPRS agitation, Cohen-Mansfield Agitation Inventory total and Physical Self Maintenance Scale between mood stabilizers and placebo. Only one of these studies was free of methodological limitations (Jadad score=5). In conclusion, based on the existing evidence, mood stabilizers are ineffective or even harmful as a treatment for AD.

Keywords

Alzheimer’s disease / behavioral and psychological symptoms / mood stabilizers / meta-analysis

References

[1] PaulsenJ.S., SalmonD.P., ThalL.J., et al.. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology, 2000, 54(10): 1965-1971

[2] TractenbergR.E., WeinerM.F., ThalL.J.. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci, 2002, 14(1): 11-18

[3] Alexopoulos GS, Silver JM, Kahn DA, et al. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia. Postgrad Med, 1998,Spec No:1-88

[4] AlexopoulosG.S., StreimJ., CarpenterD., et al.. Using antipsychotic agents in older patients. J Clin Psychiatry, 2004, 65(Suppl2): 5-104

[5] Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev, 2009,(3):CD003945

[6] JadadA.R., MooreR.A., CarrollD., et al.. Assessing the quality of reports of randomized clinical trials: Is blinding necessary. Control Clin Trials, 1996, 17(1): 1-12

[7] PorsteinssonA.P., TariotP.N., ErbR., et al.. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry, 2001, 9(1): 58-66

[8] SivalR.C., HaffmansP.M., JansenP.A., et al.. Sodium valproate in the treatment of aggressive behavior in patients with dementi-A randomized placebo controlled clinical trial. Int J Geriatr Psychiatry, 2002, 17(6): 579-585

[9] TariotP.N., SchneiderL.S., MintzerJ.E., et al.. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Rev, 2001, 62: 51-67

[10] SommerO.H., AgaO., CvancarovaM., et al.. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord, 2009, 27(2): 155-163

[11] TariotP.N., ErbR., PodgorskiC.A., et al.. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry, 1998, 155(1): 54-61

[12] TariotP.N., ErbR., LeiboviciA., et al.. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc, 1994, 42(11): 1160-1166

[13] LemkeM.R.. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry, 1995, 56(8): 354-357

[14] GleasonR.P., SchneiderL.S.. Carbamazepine treatment of agitation in Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry, 1990, 51(3): 115-118

[15] HampelH., EwersM., BürgerK., et al.. Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry, 2009, 70(6): 922-931

[16] LeyheT., EschweilerG.W., StranskyE., et al.. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis, 2009, 16(3): 649-656

[17] HerrmannN., LanctôtK.L., RothenburgL.S., et al.. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer’s disease. Dement Geriatr Cogn Disord, 2007, 23(2): 11611-11619

[18] MacdonaldA., BriggsK., PoppeM., et al.. A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry, 2008, 23(7): 704-711

[19] OlinJ.T., FoxL.S., PawluczykS., et al.. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry, 2001, 9(4): 400-405

[20] ProfennoL.A., JakimovichL., HoltC.J., et al.. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer’s disease. Curr Alzheimer Res, 2005, 2(5): 553-558

[21] TariotP.N., RamanR., JakimovichL., et al.. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry, 2005, 13(11): 942-949

[22] MckhannG., DrachmanD., FolsteinM., et al.. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 1984, 34(7): 939-944

[23] CummingsJ.L., MegaM., GrayK., et al.. The Neuropsyc iatric Inventory: comprehensive assessment of psychopat hology in dementia. Neurology, 1994, 44(12): 2308-2314

[24] SchneiderL.S., DagermanK.S., InselP.. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294(15): 1934-1943

[25] HerrmannN., LanctôtK.L.. Do atypical antipsychotics cause stroke?. CNS Drugs, 2005, 19(2): 91-103

[26] TariotP.N., LoyR., RyanJ.M., et al.. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev, 2002, 54(12): 1567-1577

[27] LöscherW.. Valproate: a reappraisal of its pharmacody namic properties and mechanisms of action. Prog Neurobiol, 1999, 58(1): 31-59

[28] MarkR.J., AshfordJ.W., GoodmanY., et al.. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging, 1995, 16(2): 187-198

[29] FarberN.B., NewcomerJ.W., OlneyJ.W.. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer’s disease. Prog Brain Res, 1998, 116: 421-437

[30] GongC.X., LiuF., Grundke-IqbalI., et al.. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm, 2005, 112(6): 813-838

[31] RunX., LiangZ., ZhangL., et al.. Anesthesia induces phosphorylation of tau. J Alzheimers Dis, 2009, 16(3): 619-626

[32] LiangZ., LiuF., IqbalK., et al.. Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis, 2009, 17(3): 531-539

[33] WangH., ZhaoH., YeY., et al.. Focal cerebral ischemia induces Alzheimer’s disease-like pathological change in rats. J Huazhong Univ Sci Technol [Med Sci], 2010, 30(1): 29-36

[34] ZhouJ., ChenJ., FengY.. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J Huazhong Univ Sci Technol [Med Sci], 2006, 26(3): 272-274

[35] TajesM., Gutierrez-cuestaJ., FolchJ., et al.. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol, 2008, 67(6): 612-623

[36] GhosalK., VogtD.L., LiangM., et al.. Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA, 2009, 106(43): 18367-18372

[37] CohenP., FrameS.. The renaissance of GSK3. Nat Rev Mol Cell Biol, 2001, 2(10): 769-776

[38] ChenG., HuangL.D., JiangY.M., et al.. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem, 1999, 72(3): 1327-1305